A Phase 2 interventional study of Buccal fat reconstruction and No buccal fat reconstruction in Tonsil Neoplasm, Oropharynx Neoplasm and Transoral Robotic Surgery, sponsored by University Health Network, Toronto. Not yet recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-21.
Sponsored by University Health Network, Toronto · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Oropharyngeal Neoplasms with a site in Canada — 9 open to participants now, 14 under way, 5 of them phase 3. Oropharyngeal Neoplasms · Canada.
Among the 25 studies in Oropharyngeal Neoplasms with a site in Canada, this one is the 14th largest by planned enrollment of the 20 interventional ones that give a count, is one of 3 that started in 2025, is one of 6 in phase 2, reaches primary completion later than 8 of the 13 other live ones, and was the 23rd registered.
370 studies on the registry are indexed under Oropharyngeal Neoplasms; 104 are open to participants now.
Browse Oropharyngeal Neoplasms studies →9 of the 25 studies in Oropharyngeal Neoplasms with a site in Canada are open now. Recruiting first, the newest first:
Corbus Pharmaceuticals Inc. · Sites in Canada, United States, Austria and 11 more countries
Ages 18+
Canadian Cancer Trials Group · Sites in Canada, United States
Ages 18+
Centre hospitalier de l'Université de Montréal (CHUM) · Sites in Canada
Ages 18–65
National Cancer Institute (NCI) · Sites in Canada, United States
Ages 18+
Centre hospitalier de l'Université de Montréal (CHUM) · Sites in Canada, Australia
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 89 Oropharyngeal Neoplasms studies recruiting now, 76 (85%) set no upper age limit and 5 (6%) stop at 75 or younger; none take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 10 · Phase 3 8 · Phase 4 1
First in 1999; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 52 across 265 interventional studies indexed under Oropharyngeal Neoplasms.
Median enrollment 76 across the 20 interventional studies, 65 across the 3 observational. Of the 11 that completed or were terminated, 4 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 25 have an industry lead sponsor. The 10 most frequent:
University Health Network, Toronto is the lead sponsor of 1,441 studies on the registry; 298 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 3 (18%) have results posted.
University Health Network, Toronto has 4 studies filed under Oropharyngeal Neoplasms — fewer than ten, so there is no comparison to draw.
4 of the studies in Oropharyngeal Neoplasms with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04901234Centre hospitalier de l'Université de Montréal (CHUM)Adaptive RadioTherapy for OroPharynx Cancer | 2026-12 |
| NCT06578871London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sSurgery and Reducing Ionizing Radiation of the Unknown Primary | 2026-12-31 |
| NCT06965738University Health Network, TorontoBuccal Fat for Transoral Robotic Lateral Oropharyngectomy Defects to and Postoperative Pain | 2027-04-01 |
| NCT05172245National Cancer Institute (NCI)Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer | 2027-07-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 25 studies in Oropharyngeal Neoplasms with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this randomized clinical trial is to determine the pain intensity during rest and swallowing in patients undergoing transoral robotic surgery for tonsil lesions with and without buccal fat reconstruction. The main question it aims to answer is: does buccal fat after transoral robotic surgery reduce pain after surgery? Additional questions to be explored include if there is a difference in swallowing, complication rates, pain medication usage, and feeding tube usage. Participants will be asked to rate their pain and swallowing on a visual analogue scale after surgery. The group will be compared compared to a control group that undergoes transoral robotic surgery without buccal fat reconstruction.
Trans-oral robotic surgery (TORS) for oropharyngeal cancers have transformed how oropharyngeal cancers are managed, allowing for minimally invasive surgical access to remove tumors of the tonsil and base of tongue. While large incisions and open approaches can be avoided, oropharyngeal defects following TORS are traditionally left as an open wound to heal by secondary intention, resulting in significant postoperative pain, and possibly dysphagia and dehydration.
While this has been highlighted as a key outcome measure, studies on acute pain following TORS have not had any standardization regarding the timing of pain measurement, and pain assessment. Only one study has assessed pain during 'movement-related pain', such as swallowing, which has been advocated as a key metric. Most studies used a visual analogue scale, however, majority failed to describe the timing of pain assessment relative to administration of analgesia, time of day, or diet. Overall, pain ratings and opioid utilization were highly variable between studies resulting in pain ratings ranging widely from 2.5-8 in the first few days postoperatively.
Based on the current evidence, multimodal analgesia resulted in the lowest pain ratings following TORS, with those that included gabapentin, a COX-2 inhibitor and acetaminophen having excellent pain control in the early postoperative period. Using these regimens, Castellanos et al. found that postoperative opioid consumption significantly decreased in the first three postoperative days. Clayburgh, et al. identified that addition of perioperative corticosteroids was safe and significantly improved diet consistency, and decreased length of hospital stay, though pain scores were minimally affected.
No study thus far has assessed the impact of surgical interventions on postoperative pain and swallowing. This single center, phase II, randomized control trial aims to evaluate the impact of the buccal fat rotational flap on the postoperative pain following TORS.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Require a transoral robotic lateral oropharyngectomy as a result of the following conditions :
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Transoral lateral oropharyngectomy without buccal fat reconstruction
Procedure: No buccal fat reconstruction
Transoral lateral oropharyngectomy with buccal fat reconstruction
Procedure: Buccal fat reconstruction
Ipsilateral buccal fat rotation flap for reconstruction of lateral oropharyngectomy defect
No reconstruction of lateral oropharyngectomy defect
Postoperative pain during rest and swallowing
Postoperative pain during rest and swallowing on visual analogue scale at multiple time points
Time frame: Once each at the following timepoints: 1-2 week preoperatively, postoperative day 1-3, postoperative day 7-10, postoperative day 21-28
Surgical Complications
Surgical complications and adverse events within 30 days postoperatively using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTC-AE v4.0)
Time frame: 30 days postoperatively
Opioid usage
Determine opioid usage
Time frame: 30 days postoperatively
Postoperative Hemorrhage
Postoperative hemorrhage after TORS
Time frame: 30 days postoperatively
Speech and Swallowing
Determine postoperative speech and swallowing using the Performance Status Scale for Head and Neck (PSS-HN)
Time frame: Once each at the following timepoints: 1-2 week preoperatively, postoperative day 7-10, postoperative day 21-28
Oral Diet
Determine food consistencies achieved at short post-operative follow up (per PSS-HN)
Time frame: Once each at the following timepoints: 1-2 week preoperatively, postoperative day 7-10, postoperative day 21-28
Feeding Tube Placement
Determine rate of feeding tube placement
Time frame: 30 days postoperatively
Blood Glucose
Determine blood glucose levels
Time frame: 30 days postoperatively
Plan to share: Yes — De-identified data, randomization, primary and secondary outcomes
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: May 2027-May 2037
Access criteria: IPD can be shared on a case by case basis by contacting the principal investigator, data will be de-identified, extent of data will be determined and decided upon by the principal investigator, data will be shared via secure email and data transfer agreement
No publications or documents are linked to this record.
Start is estimated for Jun 2025; primary completion for Apr 2027, 22 months later.
Of 63 non-industry phase 2 interventional studies under Oropharyngeal Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 49 and three quarters within 99. This study's planned 22 months is below that.
Counting every sponsor, half of 64 studies reached it within 63 months; a quarter within 49 and three quarters within 99.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Health Network, Toronto →